Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 6
2006 1
2007 3
2008 2
2009 2
2010 1
2011 5
2012 2
2013 6
2014 2
2019 3
2020 5
2021 2
2022 9
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean cirillo bastide (1 results)?
Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression.
Baboudjian M, Breda A, Rajwa P, Gallioli A, Gondran-Tellier B, Sanguedolce F, Verri P, Diana P, Territo A, Bastide C, Spratt DE, Loeb S, Tosoian JJ, Leapman MS, Palou J, Ploussard G. Baboudjian M, et al. Among authors: bastide c. Eur Urol Oncol. 2022 Dec;5(6):617-627. doi: 10.1016/j.euo.2022.07.004. Epub 2022 Aug 4. Eur Urol Oncol. 2022. PMID: 35934625 Review.
Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis.
Baboudjian M, Moser D, Yanagisawa T, Gondran-Tellier B, Compérat EM, Ambrosetti D, Daniel L, Bastide C, Shariat SF, Lechevallier E, Diana P, Breda A, Pradere B, Boissier R. Baboudjian M, et al. Among authors: bastide c. Eur Urol Open Sci. 2022 May 19;41:8-15. doi: 10.1016/j.euros.2022.04.009. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35633831 Free PMC article. Review.
Active Surveillance for Biopsy Proven Renal Oncocytomas: Outcomes and Feasibility.
Deledalle FX, Ambrosetti D, Durand M, Michel F, Baboudjian M, Gondran-Tellier B, Lannes F, Daniel L, André M, Fais PO, Savoie PH, Durand X, Rossi D, Karsenty G, Bastide C, Lechevallier E, Boissier R. Deledalle FX, et al. Among authors: bastide c. Urology. 2021 Oct;156:185-190. doi: 10.1016/j.urology.2021.05.034. Epub 2021 Jun 1. Urology. 2021. PMID: 34087310
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK, Cherif C, Omabe K, Paris C, Lannes F, Audebert S, Baudelet E, Hamimed M, Barbolosi D, Finetti P, Bastide C, Fazli L, Gleave M, Bertucci F, Taïeb D, Rocchi P. Le TK, et al. Among authors: bastide c. Mol Ther. 2023 Feb 1;31(2):471-486. doi: 10.1016/j.ymthe.2022.08.005. Epub 2022 Aug 13. Mol Ther. 2023. PMID: 35965411 Free PMC article.
48 results